1. Lee, ES, Bang, D, Lee, S. Dermatologic manifestation of Behcet's Disease. Yonsei Med J. 1997;38(6):380-389.
Google Scholar | Crossref | Medline2. Mizushima, Y, Inaba, G, Mimura, Y, et al. Diagnostic criteria for Behcet's Disease in 1987 and guideline for treating Behcet's Disease. Saishin Igaku. 1988;43(5):391-393.
Google Scholar3. Rustin, MH, Gilkes, JJ, Robinson, TW. Pyoderma gangrenosum associated with Behcet's Disease: treatment with thalidomide. J Am Acad Dermatol. 1990;23(5):941-944.
Google Scholar | Crossref | Medline | ISI4. Chams-Davatchi, C, Shizarpour, M, Davatchi, F, et al. Extensive pyoderma gangrenosum-like lesion in two cases of Behcet's Disease, responding only to cyclosporine. Adv Exp Med Biol. 2003;528:337-338.
Google Scholar | Crossref | Medline5. Düzgün, N, Ates, A, Aydintug, OT, et al. Characteristics of vascular involvement in Behcet's Disease. Scand J Rheumatol. 2006;35(1):65-68.
Google Scholar | Crossref | Medline6. Plotkin, GR, Patel, BR, Shah, VN. Behçet's Syndrome complicated by cutaneous leukocytoclastic vasculitis. Response to prednisone and chlorambucil. Arch Intern Med. 1985;145(10):1913-1915.
Google Scholar | Crossref | Medline7. Ozoran, K, Düzgün, N, Gurler, A, et al. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's Disease. Scand J Rheumatol. 1995;24(6):376-382.
Google Scholar | Crossref | Medline8. Kosar, A, Ozturk, M, Haznedaroglu, IC, et al. Hemostatic parameters in Behcet's Disease: a reappraisal. Rheumatol Int. 2002;22(1):9-15.
Google Scholar | Crossref | Medline9. Hizli, N, Sahin, G, Sahin, F, et al. Plasma prostacyclin levels in Behcet's Disease. Lancet. 1985;1(8443):1454.
Google Scholar | Crossref | Medline10. Ural, AU . Increased plasma endothelin-1 levels in active Behcet's Disease. Clin Rheumatol. 1997;16(6):59-61.
Google Scholar | Crossref | Medline